Enterprise Value
15.1B
Cash
1.171B
Avg Qtr Burn
N/A
Short % of Float
3.76%
Insider Ownership
0.49%
Institutional Own.
97.77%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VOXZOGO (vosoritide) Details Achondroplasia, Genetic Short Stature Conditions | Approved Quarterly sales | |
Approved Quarterly sales | ||
VOXZOGO (vosoritide) Details Achondroplasia, Genetic Short Stature Conditions | Approved Quarterly sales | |
VOXZOGO Details Genetic Short Stature Conditions, Achondroplasia, Hypochondroplasia | Phase 2 Initiation |